modelAflibercept
Extends from Pharmacolibrary.Drugs.ATC.L.L01XX44.
Information
| name: | Aflibercept | |
| ATC code: | L01XX44 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 4000 | mg |
| volume of distribution: | 6.2 | L |
| clearance: | 0.68 | L/h |
| other parameters in model implementation | ||
Aflibercept is a recombinant fusion protein acting as a decoy receptor for vascular endothelial growth factor (VEGF), inhibiting angiogenesis. It is approved for the treatment of various forms of neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema, and certain cancers, including metastatic colorectal cancer. It is currently marketed under trade names such as Eylea (for ophthalmic use) and Zaltrap (for oncological use).
Pharmacokinetics
Pharmacokinetic parameters in cancer patients after intravenous administration of aflibercept (Zaltrap), as reported in adult men and women with metastatic colorectal cancer.
References
Thai, HT, et al., & Comets, E (2011). A mechanism-based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects. British journal of clinical pharmacology 72(3) 402–414. DOI:10.1111/j.1365-2125.2011.04015.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/21575034
Syed, YY, & McKeage, K (2015). Aflibercept: A Review in Metastatic Colorectal Cancer. Drugs 75(12) 1435–1445. DOI:10.1007/s40265-015-0444-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26220913
Yoshino, T, et al., & Ohtsu, A (2013). A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer. Investigational new drugs 31(4) 910–917. DOI:10.1007/s10637-012-9895-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23179335
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.Volume | Vdp (from PK_2C) | VdpPerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | VdpPerKg (from PK_2C) | 0.9 | Volume of distribution peripheral(l/kg) |
| Pharmacolibrary.Types.Clearance | k12 (from PK_2C) | 1 | intercompartmental C-P clearance |
| Pharmacolibrary.Types.Clearance | k21 (from PK_2C) | 1 | intercompartmental P-C clearance |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | peripheralCPort (from PK_2C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral1 (from PK_2C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life | |
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral (from PK_2C) |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)